T-bet Activating Polycation:DNA Complexes for Ulcerative Colitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
T-bet deficiency in the innate immune system leads to aggressive, spontaneous ulcerative colitis and increased susceptibility to colitis and colorectal cancer, disrupting the balance between host and commensal bacteria, and current treatments are inadequate in managing these conditions.
Innovation Solution
Increasing T-bet activity in cells of the innate immune system, such as dendritic cells, using polycation:DNA complexes conjugated with antibodies targeting specific immune cells, and administering antibiotics or probiotics to modulate the immune response and prevent bacterial colonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T-bet activity is increased in innate immune system cells, then ulcerative colitis and colorectal cancer are treated/prevented, but the complexity of the treatment approach increases
Solution Approach 1:
The patent combines multiple therapeutic modalities into a unified treatment approach: polycation:DNA complexes conjugated with antibodies are administered alongside antibiotics or probiotics. This merging of immunomodulation (via T-bet activation) and microbial management (via antibiotics/probiotics) creates a comprehensive treatment that addresses both the immune system dysfunction and the bacterial dysbiosis associated with ulcerative colitis and colorectal cancer
Solution Approach 2:
The polycation:DNA complex conjugated with antibodies serves multiple functions simultaneously: it acts as a delivery vehicle for T-bet activating sequences, functions as an immunomodulator to restore innate immune response, and can be targeted to specific cell types through antibody selection. This multi-functionality reduces the need for separate therapeutic agents and simplifies the overall treatment regimen
2Reliability
If polycation:DNA complexes conjugated with antibodies are used to increase T-bet activity, then immune response is modulated effectively, but the manufacturing complexity increases
Solution Approach 1:
The treatment approach segments the therapeutic function into modular components: the polycation:DNA complex provides the T-bet activating sequence, the antibody provides the targeting and specificity, and these can be combined in a controlled manner. This segmentation allows for standardized production of each component separately, then assembly into the final conjugate, reducing overall manufacturing complexity compared to creating a completely novel single-agent therapy
Solution Approach 2:
The polycation:DNA complex acts as an intermediary carrier that bridges the gap between the antibody (targeting agent) and the T-bet activating sequence (therapeutic payload). This intermediary structure facilitates controlled delivery and release, enabling manufacturers to use established antibody conjugation techniques while maintaining the integrity and functionality of the T-bet activating DNA sequence
3Object-affected harmful factors
If antibiotics or probiotics are administered to modulate immune response, then bacterial colonization is reduced, but the precision of immune system targeting decreases
Solution Approach 1:
The patent applies local quality by using different therapeutic agents with different specificities in combination: the polycation:DNA complex conjugated with antibodies provides precise, targeted immunomodulation to specific innate immune cells (macrophages, dendritic cells, NK cells) through antibody-mediated targeting, while antibiotics and probiotics provide broader, less specific effects on the microbial community. This localized precision at the cellular level combined with broad-spectrum microbial management creates a synergistic treatment approach that overcomes the limitations of each individual modality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively treats and prevents ulcerative colitis and colorectal cancer by regulating TNF-α production, maintaining the epithelial barrier, and reducing bacterial colonization, as demonstrated by the abolition of colitis and carcinoma in T-bet deficient animals.
Implementation Method 1
polycation:DNA complexes conjugated with antibodies targeting specific immune cells
Implementation Method 2
polycation:DNA complexes
Implementation Method 3
T-bet controls the response of the mucosal immune system to commensal bacteria by regulating TNF-α production in cells of the innate immune system
Implementation Method 4
administering antibiotics or probiotics to modulate the immune response and prevent bacterial colonization
Implementation Method 5
feeding T-bet deficient animals probiotics abolishes ulcerative colitis
Data Source
AI summary
The instant invention is based, at least in part, on the discovery that T-bet maintains host commensal relationships in the gastrointestinal tract. Accordingly, this invention provides methods of treating and/or preventing ulcerative colitis, and/or colon cancer, and/or preventing colonization of a subject's gastrointestinal tract with commensal bacteria that promote ulcerative colitis as well as methods of identifying agents that treat and prevent the same.